Citations

Showing 10 of 108083 citations.

Post‐cardioversion atrial stunning – Not to be forgotten
Naqvi, Tasneem Z. , Kurt, Merve, Naqvi, Tasneem Z , Kurt, Merve

Mayo Clinic

Echocardiography | January 4, 2023 | Volume: 40 | Issue: 3 | Pages: 266-270

10.1111/echo.15517 | PMID 36597407 Get It

AbstractWe present a case of a 60‐year‐old male who was found to be in atrial fibrillation during routine evaluation. Anticoagulation was initiated for 36 h and he was referred for TEE‐guided electrical cardioversion. There was no thrombus identified in the left atrial appendage, however, the appendage was large and had a tongue‐like accessory lobe along with spontaneous contrast in the left atrium and its appendage. TEE probe was not withdrawn, patient underwent successful cardioversion with 200 joules and developed a marked increase in left atrial and left atrial appendage spontaneous contrast along with the development of tear drop shaped thrombus in the left atrial appendage immediately after cardioversion, which rapidly became more dense. There was an associated marked decrease in appendage velocities. Patient was hospitalized to initiate low molecular weight heparin. This case highlights the need for vigilance in patients with an unknown duration of atrial fibrillation, who have received a short duration of anticoagulant therapy and who have adverse appendage anatomy as thrombus may develop immediately after cardioversion despite anticoagulation.
Structure-Based Identification of Natural-Product-Derived Compounds with Potential to Inhibit HIV-1 Entry
Ugwu-Korie, Nneka, Quaye, Osbourne , Wright, Edward , Languon, Sylvester , Agyapong, Odame , Broni, Emmanuel , Gupta, Yash , Kwofie, Samuel K., Kwofie, Samuel K , Gupta, Yash , Kempaiah, Prakasha

Mayo Clinic

Molecules | January 4, 2023 | Volume: 28 | Issue: 2 | Pages: 474

10.3390/molecules28020474 | PMID 36677538 Get It

Broadly neutralizing antibodies (bNAbs) are potent in neutralizing a wide range of HIV strains. VRC01 is a CD4-binding-site (CD4-bs) class of bNAbs that binds to the conserved CD4-binding region of HIV-1 envelope (env) protein. Natural products that mimic VRC01 bNAbs by interacting with the conserved CD4-binding regions may serve as a new generation of HIV-1 entry inhibitors by being broadly reactive and potently neutralizing. This study aimed to identify compounds that mimic VRC01 by interacting with the CD4-bs of HIV-1 gp120 and thereby inhibiting viral entry into target cells. Libraries of purchasable natural products were virtually screened against clade A/E recombinant 93TH057 (PDB: 3NGB) and clade B (PDB ID: 3J70) HIV-1 env protein. Protein–ligand interaction profiling from molecular docking and dynamics simulations showed that the compounds had intermolecular hydrogen and hydrophobic interactions with conserved amino acid residues on the CD4-binding site of recombinant clade A/E and clade B HIV-1 gp120. Four potential lead compounds, NP-005114, NP-008297, NP-007422, and NP-007382, were used for cell-based antiviral infectivity inhibition assay using clade B (HXB2) env pseudotype virus (PV). The four compounds inhibited the entry of HIV HXB2 pseudotype viruses into target cells at 50% inhibitory concentrations (IC50) of 15.2 µM (9.7 µg/mL), 10.1 µM (7.5 µg/mL), 16.2 µM (12.7 µg/mL), and 21.6 µM (12.9 µg/mL), respectively. The interaction of these compounds with critical residues of the CD4-binding site of more than one clade of HIV gp120 and inhibition of HIV-1 entry into the target cell demonstrate the possibility of a new class of HIV entry inhibitors.
Nanoparticle Based Cardiac Specific Drug Delivery
Son, Yura , Jang, Michelle, Wang, Shu , Zhu, Wuqiang , Son, Yura , Wang, Shu , Zhu, Wuqiang , Li, Dong

Mayo Clinic

Biology | January 4, 2023 | Volume: 12 | Issue: 1 | Pages: 82

10.3390/biology12010082 | PMID 36671774 Get It

Heart failure secondary to myocardial injuries is a leading cause of death worldwide. Recently, a growing number of novel therapies have emerged for injured myocardium repairment. However, delivering therapeutic agents specifically to the injured heart remains a significant challenge. Nanoparticles are the most commonly used vehicles for targeted drug delivery. Various nanoparticles have been synthesized to deliver drugs and other therapeutic molecules to the injured heart via passive or active targeting approaches, and their targeting specificity and therapeutic efficacies have been investigated. Here, we summarized nanoparticle-based, cardiac-specific drug delivery systems, their potency for treating heart diseases, and the mechanisms underlying these cardiac-targeting strategies. We also discussed the clinical studies that have employed nanoparticle-based cardiac-specific drug delivery.
Exosomes: The Latest in Regenerative Aesthetics
Vyas, Krishna S. , Kaufman, Joely , Munavalli, Girish S., Robertson, Kiran, Wyles, Saranya P. , Behfar, Atta

Mayo Clinic

Regenerative Medicine | January 4, 2023 | Volume: 18 | Issue: 2 | Pages: 181-194

10.2217/rme-2022-0134 | PMID 36597716 Get It

Patient characteristics associated with delayed neurological improvement following acute ischemic stroke: A systematic review and meta-analysis
Kobeissi, Hassan , Ghozy, Sherief , Seymour, Trey , Bilgin, Cem , Liu, Michael , Kadirvel, Ramanathan , Brinjikji, Waleed , Kallmes, David F. , Seymour, Trey J , Kallmes, David F , Ghozy, Sherief , Kobeissi, Hassan , Liu, Michael , Bilgin, Cem , Rabinstein, Alejandro A.

Mayo Clinic

Interventional Neuroradiology | January 4, 2023 | Volume: 32 | Issue: 3 | Pages: 639-647

10.1177/15910199221149787 | PMID 36597678 Get It

Background Delayed neurological improvement (DNI) is a phenomenon that involves patient improvement in the absence of early neurological change following treatment for acute ischemic stroke. The patient characteristics associated with this condition are largely unexplored. Methods Following the PRISMA guidelines, a systematic review of the English language literature was conducted using PubMed, Embase, Web of science, and Scopus. We calculated pooled odds ratios (ORs), mean differences (MDs), and their corresponding 95% confidence intervals (CIs) to test the association between patient characteristics and achievement of DNI. Results Seven studies, with 3266 patients, were included in our analysis. All studies reported a different definition of DNI, with five studies focusing on rates of good functional outcome at 90 days post-treatment in the absence of early neurological improvement. Use of intravenous thrombolytics was associated with increased rates of DNI (OR 1.96, 95% CI 1.28 to 3.00; p = 0.002). Atrial fibrillation was associated with decreased rates of DNI (OR 0.69, 95% CI 0.57 to 0.82; p < 0.001), as was hypertension (OR 0.66, 95% CI 0.53 to 0.83, p < 0.001), and diabetes mellitus (OR 0.71, 95% CI 0.56 to 0.90; p = 0.005). On average, patients who achieved DNI were 6.30 years younger than their non-DNI counterparts ( MD −6.30, 95% CI −9.19 to −3.41; p < 0.001). There were modest associations between male sex and DNI (OR 1.36, 95% CI 1.01 to 1.74, p = 0.042), and smoking and DNI (OR 1.28, 95% CI 1.03 to 1.59, p = 0.027). Conclusions DNI is a phenomenon that is not presently well understood. Lack of uniformity among definitions of DNI hinders efforts to explore DNI and the factors associated with its occurrence. Future studies should work to establish a consensus definition of DNI to determine its causes and significance more accurately.
Early Identification of Pneumonitis in Patients Irradiated for Lung Cancer—Final Results of the PARALUC Trial
Rades, Dirk , Werner, Elisa, GLATZEL, ESTHER, Bohnet, Sabine , Schild, Steven E. , TVILSTED, SØREN, Schild, Steven , Janssen, Stefan

Mayo Clinic

Cancers | January 4, 2023 | Volume: 15 | Issue: 2 | Pages: 326

10.3390/cancers15020326 | PMID 36672276 Get It

Radiotherapy of lung cancer may cause pneumonitis that generally occurs weeks or months following therapy and can be missed. This prospective trial aimed to pave the way for a mobile application (app) allowing early diagnosis of pneumonitis. The primary goal was the identification of the optimal cut-off of a score to detect pneumonitis of grade ≥2 after radiotherapy for lung cancer. Based on the severity of symptoms (cough, dyspnea, fever), scoring points were 0–9. Receiver operating characteristic (ROC)-curves were used to describe the sensitivity and specificity. The area under the ROC-curve (AUC) was calculated to judge the accuracy of the score, Youden-index was employed to define the optimal cut-off. Until trial termination, 57 of 98 patients were included. Eight of 42 patients evaluable for the primary endpoint (presence or absence of radiation pneumonitis) experienced pneumonitis. AUC was 0.987 (0.961–1.000). The highest sensitivity was achieved with 0–4 points (100%), followed by 5 points (87.5%), highest specificity with 5–6 points (100%). The highest Youden-index was found for 5 points (87.5%). The rate of patient satisfaction with the symptom-based scoring system was 93.5%. A cut-off of 5 points was identified as optimal to differentiate between pneumonitis and no pneumonitis. Moreover, pneumonitis was significantly associated with an increase of ≥3 points from baseline (p < 0.0001). The scoring system provided excellent accuracy and high patient satisfaction. Important foundations for the development of a mobile application were laid.
WHO Is Recommending against the Use of COVID-19 Convalescent Plasma in Immunocompromised Patients?
Franchini, Massimo , Casadevall, Arturo , Focosi, Daniele , Focosi, Daniele , Casadevall, Arturo , Franchini, Massimo , Joyner, Michael J.

Mayo Clinic

Life | January 4, 2023 | Volume: 13 | Issue: 1 | Pages: 134

10.3390/life13010134 | PMID 36676084 Get It

Since December 2019, SARS-CoV-2 is ravaging the globe, currently accounting for over 660 million infected people and more than 6 [...]
Treatment of a high healthcare utilizer with sepsis in a virtual hybrid hospital‐at‐home program
Paulson, Margaret R. , Torres‐Guzman, Ricardo A. , Matcha, Gautam , Ávila, Francisco R. , Maita, Karla C. , Garcia, John P. , Maniaci, Michael J. , Matcha, Gautam V , Forte, Antonio Jorge , Maniaci, Michael J , Torres, Ricardo A , Avila, Francisco R , Garcia, John P , Paulson, Margaret R , Forte, Antonio J.

Mayo Clinic

Clinical Case Reports | January 4, 2023 | Volume: 11 | Issue: 1 | Pages: No page available

10.1002/ccr3.6806 | PMID 36619489 Get It

Abstract High healthcare utilizers are often chronically ill patients who require aggressive hospital and outpatient care. We describe a patient with septic shock who was stabilized in the intensive care unit, then transitioned to a virtual hybrid hospital‐at‐home to complete both inpatient care as well as outpatient wound and rehabilitation therapy.
1005 Characterization of regulatory receptors on plasmacytoid dendritic cells in lupus
Nln, Ilona, Iwamoto, Taro, Dorschner, Jessica M., Vsetecka, Danielle, McCoy, Gabrielle A., Paredes, Jacqueline L, Jensen, Mark A, Iwamoto, Taro, McCoy, Gabrielle, Niewold, Timothy B.

Mayo Clinic

Innate Immunity | January 4, 2023 | Volume: No volume available | Issue: No issue available | Pages: A68.1-A68

10.1136/lupus-2022-lupus21century.65 Get It

626 The trajectory of Multimorbidity in patients with Systemic Lupus Erythematosus in the United States
Stevens, Maria , Heien, Herbert C., Meade, Jose, Thanarajasingam, Uma , Crowson, Cynthia S. , Duarte‐García, Alí , Stevens, Maria, Figueroa‐Parra, Gabriel , Jeffery, Molly Moore , McCoy, Rozalina G.

Mayo Clinic

Clinical Research in SLE | January 4, 2023 | Volume: No volume available | Issue: No issue available | Pages: A53-A54

10.1136/lupus-2022-lupus21century.47 Get It